Alnylam Pharmaceuticals CEO Discusses Q2 2012 Results - Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. (ALNY)

Q2 2012 Earnings Call

August 6, 2012; 04:30 pm ET

Executives

John Maraganore - Chief Executive Officer

Barry Greene - President & Chief Operating Officer

Jared Gollob - Vice President of Clinical Research

Mike Mason - Vice President of Finance & Treasurer

Cynthia Clayton - Vice President of Investor Relations & Corporate Communications

Analysts

Charles Duncan - JMP Securities

Geoff Meacham - JPMorgan

Marko Kozul - Leerink Swann

Alan Carr - Needham

Edward Tenthoff - Piper Jaffray

George Devoiko - MLB & Company

Presentation

Operator

Compare to:
Previous Statements by ALNY
» Alnylam Pharmaceuticals CEO Discusses Q3 2010 Results – Earnings Call Transcript
» Alnylam Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript
» Alnylam Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript
» Alnylam Pharmaceuticals, Inc. Q4 2008 Earnings Call Transcript

Good day ladies and gentlemen and thank you for standing by. Welcome to the Alnylam Pharmaceuticals conference call to discuss the second quarter 2012 financial results. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the company’s request.

I would now like to turn the call over to the company. You may proceed.

Cynthia Clayton

Good afternoon. I’m Cynthia Clayton, Vice President of Investor Relations and Corporate Communications at Alnylam. With me today are John Maraganore, Chief Executive Officer; Barry Greene, President and Chief Operating Officer; Jared Gollob, Vice President of Clinical Research; and Mike Mason, Vice President of Finance and Treasurer. Akshay Vaishnaw, our Chief Medical Officer could not be with us today due to travel plans.

For those of you participating via conference call, the slides we have made available via webcast can also be accessed by going to the Investors page of our website www.alnylam.com.

During today’s call as outlined in slide two, John will provide some introductory remarks and provide general context. Jared will summarize the clinical progress with our Alnylam 5x15 program. Mike will review our financials and guidance, and Barry will provide a brief update on progress with our partner programs and also provide a summary of our business highlights and goals. We will then open the call for your questions.

1 2 3 Next › Last »